Finance ❯ Corporate Finance ❯ Revenue Growth ❯ Xeris Biopharma

2025 Revenue and EBITDA

Xeris Biopharma Sets 2026 Revenue Outlook at $375–$390 Million, Targets H2 Start for XP-8121 Phase III

2025 profitability positions the company to step up 2026 investment focused on growth plus exclusivity protection.